|
|||||
|
|
Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST |
|
| Authors: | Teranishi Ryugo Takahashi Tsuyoshi Nishida Toshirou Kurokawa Yukinori Nakajima Kiyokazu Koh Masahiro Nishigaki Takahiko Saito Takuro Yamamoto Kazuyoshi Yamashita Kotaro Tanaka Koji Makino Tomoki Motoori Masaaki Omori Takeshi Hirota Seiichi Hayashi Yoshito Takehara Tetsuo Eguchi Hidetoshi Doki Yuichiro |
| Affiliation: | 1.Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2-E2 Yamadaoka, Suita, Osaka, 565-0871, Japan ;2.Department of Surgery, Japan Community Health Care Organization Osaka Hospital, 4-2-78, Fukushima, Fukushima-Ku, Osaka, Japan ;3.Department of Surgery, Osaka General Medical Center, 3-1-56, Bandai-Higashi, Sumiyoshi-Ku, Osaka, Osaka, 558-8558, Japan ;4.Department of Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka, Osaka, 541-8567, Japan ;5.Department of Surgical Pathology, Hyogo Medical University School of Medicine, 1-1, Mugogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan ;6.Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan ; |
| Abstract: | International Journal of Clinical Oncology - Imatinib mesylate (IM) is the standard chemotherapy for patients with gastrointestinal stromal tumors (GISTs) and has a favorable safety profile.... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |